Regulatory 2025-04-16 | Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1 PDF Report Presentation Webcast
Regulatory 2025-04-11 | Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion PDF ESEF Report Presentation Webcast
2025-04-08 | Ascelia Pharma Announces Publication of Orviglance Study in Investigative Radiology PDF Report Presentation Webcast
Regulatory 2025-04-04 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
2025-04-04 | Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference PDF Report Presentation Webcast
Regulatory 2025-03-31 | The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025 PDF Report Presentation Webcast
Regulatory 2025-03-18 | Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025 PDF Report Presentation Webcast
Regulatory 2025-02-25 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025 PDF Report Presentation Webcast
Regulatory 2025-02-12 | Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-02-07 | Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study PDF Report Presentation Webcast
Regulatory 2025-01-30 | NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
2025-01-27 | Ascelia Pharma Announces Acceptance of Three Scientific Abstracts with SPARKLE Phase 3 Data at the European Society of Gastrointestinal and Abdominal Radiology Annual Meeting PDF Report Presentation Webcast
2024-12-23 | Ascelia Pharma Patent Granted in China for Second Generation Orviglance PDF Report Presentation Webcast
2024-12-17 | Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025 PDF Report Presentation Webcast
2024-12-02 | Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting PDF Report Presentation Webcast
Regulatory 2024-11-29 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-11-22 | Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program PDF Report Presentation Webcast
Regulatory 2024-11-07 | Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025 PDF Report Presentation Webcast
